Inventiva joins the Euronext Tech Leaders segment
Daix (France), Long Island City (New York, United States), June 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that it will join the Euronext Tech Leaders initiative, a new Euronext segment comprised of more than 100 high-growth and leading Tech companies across Europe.
Frédéric Cren, Chairman, Chief Executive Officer and cofounder of Inventiva, stated: “We are proud to join other Tech Leaders in this new segment. This is a recognition of our successes and our global potential as a tech-driven biopharmaceutical company, and we are confident that being part of this international initiative will bring further exposure to Inventiva. This is a great tribute to the work and dedication of all Inventiva employees.”
To be included, companies must meet a specific set of financial criteria, including a market capitalization of € 300 million and minimum growth rate conditions. This segment aims to be a catalyst for the next generation of Tech Leaders, which stand to benefit from Euronext’s strong visibility and global investor base. Investors will be able to track Euronext Tech Leaders with a new, dedicated index that becomes available in July.
Download PDF